e39 peptide vaccine
Vaccineexperimental
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2012 (NCT01580696)
Timeline
2010s
- Jan 1, 2012
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Tumor antigensImmunity, active
immunity, active - tumor antigen
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- e39 peptide vaccine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02019524 | Phase 1/Phase 2 (Phase 2) | Sep 1, 2013 | San Antonio Military Medical Center, United States Army, University of Texas at Houston |
| NCT01580696 | Phase 1/Phase 2 (Phase 2) | Apr 1, 2012 | Mid-Atlantic Gynecologic Oncology & Pelvic Surgical Associates, San Antonio Military Medical Center, United States Army |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| San Antonio Military Medical Center | Academic/Hospital | 2 | 2 | 1 | 2012 |
| United States Army | Government | 2 | 0 | 1 | 2012 |
| Mid-Atlantic Gynecologic Oncology & Pelvic Surgical Associates | Academic/Hospital | 1 | 0 | 1 | 2012 |
| University of Texas at Houston | Academic/Hospital | 1 | 0 | 1 | 2013 |
4 organizations
Page 1 / 1